Dose Insider / Analyses / Stopping Zepbound

What Happens When You Stop ZepboundHow Much Weight Comes Back, and How Fast

Updated November 20, 2026 · 27 min read · SURMOUNT-4, BMJ 2026 meta-analysis

In the trial that tested it, people who stopped Zepbound after 36 weeks regained about half of the weight they had lost within a year.

53%of the lost weight came back within a year of stopping
Weight below the start, week 88Withdrawal trial: 36 weeks on Zepbound, then half switched to placeboAt week 36, all−20.9%Stayed on Zepbound−25.3%Switched to placebo−9.9%Weight below the start, week88Withdrawal trial: 36 weeks on Zepbound, then halfswitched to placeboAt week 36, all−20.9%Stayed on Zepbound−25.3%Switched to placebo−9.9%

53% of the lost weight came back within a year of stopping.

On this page

Those who stayed on it lost a little more. One in six of those who stopped still had most of their loss a year later.

This page puts both outcomes into your own numbers, then goes through what the trials measured: how many people regain and how much, how fast the weight returns, what happens to blood pressure and waist, what a lower dose held, and what is known about exercise, tapering and restarting.

What would stopping look like in my numbers?

Enter your weight before Zepbound and your weight now. The calculator applies the average results of the two halves of the withdrawal trial to the weight you have lost.

Your two pathsSURMOUNT-4
Unit
Share of the lost weight that came back
If you stop—
If you stay on—
Stopped, trial averageStayed on, trial average

Log your weight in the app and see your own line next to the trial's.

Open the app

The numbers along the bottom are weeks from now. The dotted line is your weight before Zepbound, and the shaded wedge is the regain group you picked. Trial averages after 36 weeks on 10 or 15 mg; a single person can land well away from them. This is not a prediction for you.

The two lines are the two halves of one trial. Everyone in it took Zepbound for 36 weeks. Then half were switched, without knowing it, to injections that contained no drug, and half carried on. A year later both groups were weighed again.2 The coral line applies the first group's average result to your loss, and the mint line applies the second group's.

The calculator opens with the trial's average participant, who weighed 237 lb at the start and 188 lb after 36 weeks. A year after stopping, that person was back at about 214 lb: 26 lb of the 49 lb had returned. A year of staying on the drug took the same person to about 178 lb.

The shaded wedge is there because the average hides a wide spread. A later analysis of the same trial sorted the people who stopped into four groups by how much of their loss came back. The buttons switch between those groups, and the sentence under the chart gives each group's range in your weight.3

Weight beforeAfter a 20.9% loss lbA year after stopping lbA year of staying on lb
200 lb158180150
250 lb198225187
300 lb237270224
350 lb277315262

Our arithmetic from the trial averages: 53% of the lost weight back after stopping, a further 5.5% of current weight lost after staying on.

What did the trial that tested stopping find?

The trial is called SURMOUNT-4, and it was built to answer one question: what happens to the weight if the drug is taken away. It enrolled 783 adults with obesity, or with overweight and a weight-related condition, and without diabetes. All of them took Zepbound for 36 weeks, with the dose raised to 10 or 15 mg, whichever was the highest they tolerated.2

Not everyone reached week 36. The label reports that 14.4% left the treatment before that point, and side effects were the most common reason, given by 6.8% of all who started.1 The 670 who remained had lost 20.9% of their weight on average, going from 107.3 kg (237 lb) to 85.2 kg (188 lb). They were then assigned by chance, 335 to each group, to continue Zepbound or to receive placebo for 52 weeks. Neither they nor the study staff knew who was in which group.

Stayed on ZepboundSwitched to placebo
People335335
Weight change, week 36 to week 88−5.5%+14.0%
Loss from the starting weight at week 8825.3%9.9%
Kept at least 80% of the loss89.5%16.6%
Stopped the study injections early10.4%17.9%

SURMOUNT-4, JAMA 2024, and Study 4 in the Zepbound label. Percent changes in the second row are counted from the weight at week 36.

The group that stopped gained 14.0% on top of their week-36 weight. The group that continued lost another 5.5%. The gap between them after a year was 19.4 percentage points.2 Counted from the very beginning, the people who stopped were still 9.9% below their starting weight at week 88, and those who continued were 25.3% below it.

Put as a share of the loss: of the 20.9 points lost on the drug, 11 came back within a year of stopping. That is 53%, a little over half.

Diet and activity advice continued, and the weight still returned

One detail of the design matters for reading the result. According to the label, every participant received lifestyle counselling from the first dose to the end of the trial: instruction on a diet with a deficit of about 500 calories a day and a recommendation of at least 150 minutes of physical activity a week.1 The people switched to placebo kept getting that counselling for the whole year. They regained anyway.

So the trial does not describe people who gave up on diet and exercise advice the day the drug stopped. It describes what the same advice achieved once the drug was no longer there.

What the trial's authors concluded

The published conclusion is one sentence: withdrawing tirzepatide "led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction".2 The label's own wording for what Zepbound is for points the same way. The drug is approved "to reduce excess body weight and maintain weight reduction long term", and that last phrase describes continued use.1

Does everyone regain the weight?

No. The trial counted how many people still had at least 80% of their weight loss at week 88. Among those who stopped, it was 16.6%, about one person in six. Among those who continued, it was 89.5%.2

Who kept the lossSURMOUNT-4
After week 36 they
Kept at least 80% of the lossKept less

Each dot is one person in a hundred. Weight at week 88, a year after the groups were split.

A second analysis, published in 2026, looked more closely at the people who stopped. It took the 308 participants who had lost at least 10% by week 36 and were then switched to placebo, and sorted them by the share of that loss they had regained a year later.3

Share of the lost weight regainedPeopleOf 308For the average loss of 49 lb
Less than a quarter5417.5%under 12 lb back
A quarter to a half7725.0%12 to 24 lb back
Half to three quarters10333.4%24 to 37 lb back
Three quarters or more7424.0%37 lb or more back

Horn and colleagues, JAMA Internal Medicine 2026. The last column is our arithmetic for the trial's average loss.

The largest group, a third of the people, regained between half and three quarters of their loss. About one in four regained three quarters or more. About one in six regained less than a quarter. Taken together, 82.5% regained at least a quarter of what they had lost.

The obvious next question is what set the one in six apart. The analysis does not answer it. The authors report that the four groups were similar at the start of the trial in their demographic and clinical characteristics.3 Nothing recorded before treatment marked out the people who would later hold their weight without the drug.

How fast does the weight come back?

In SURMOUNT-4 the gain of 14.0% over 52 weeks works out, for the average participant at 85.2 kg, to about 11.9 kg (26 lb) in the year. That is close to 1 kg, or 2.2 lb, a month.

A meta-analysis published in the BMJ in 2026 pooled the evidence across drugs. Its authors searched for every study in which adults took a weight-loss medicine for at least 8 weeks and were then followed for at least 4 weeks after stopping. They found 37 studies with 9,341 participants and estimated the monthly rate of regain for three sets of drugs.4

DrugsRegain per monthRegain in the first yearProjected return to starting weight
Any weight-loss medicine0.4 kg (0.9 lb)4.8 kg (10.6 lb)1.7 years
All GLP-1-type drugs0.5 kg (1.1 lb)6.0 kg (13.2 lb)1.6 years
Semaglutide and tirzepatide0.8 kg (1.8 lb)9.9 kg (21.8 lb)1.5 years

West and colleagues, BMJ 2026. The last column is a projection from the model, with a range of 1.0 to 1.9 years for the newer drugs. No trial followed people that long after stopping.

The two sources agree closely. The pooled estimate for semaglutide and tirzepatide is 9.9 kg in the first year, and the single tirzepatide trial gives 11.9 kg for its average participant. Both are averages over people who had lost around a fifth of their weight, so someone who has lost less should expect a smaller figure in kilograms.

The newer drugs show the fastest regain in kilograms. They also produce the largest losses, so there is more to come back. The 1.5-year figure is a projection, drawn by extending the measured rate forward. The longest follow-up in the pooled studies was 104 weeks, and the average was 32 weeks.

The same paper compared stopping a medicine with finishing a behavioural weight-loss programme, the kind built on diet and activity support. Weight returned faster after medicines, by 0.3 kg a month, and the authors found this held regardless of how much weight had been lost.4

Whether regain keeps the same pace in the second year is not known. In the semaglutide study described below, the authors saw the regain slowing towards the end of the year off treatment and wrote that they could not tell a plateau below the starting weight from a slowdown on the way back to it "without longer follow-up".5

How long does Zepbound keep working after the last dose?

The drug does not leave on the day of the last injection. The label gives tirzepatide a half-life of about 5 days, which means the amount in the body halves roughly every 5 days.1 Our model, built on that half-life, gives the level after the last dose as a share of the usual weekly peak.

Days after the last injectionLevel, share of the usual peakWhat that day is
744%the usual low, when the next dose would be due
1417%one dose missed
216%two doses missed
282.4%three doses missed
350.9%under one hundredth of the peak

Our one-compartment model with the label's half-life of 5 days, for someone who had been on a steady weekly dose.

For the first week nothing is different from any other week of treatment. In the second week the level drops below anything the body has seen since the dose settled, and by the end of the fifth week less than a hundredth of the peak is left. The article on how long Zepbound stays in the body has the full curve and a calculator by date.

The label describes how the drug lowers weight in two short sentences: "Tirzepatide decreases calorie intake. The effects are likely mediated by affecting appetite."1 As the level falls over those five weeks, that effect falls with it. The trial results quoted on this page are about weight, and they do not give a week in which hunger returned, so we cannot put a date on it. The level is the part that can be calculated.

What happens to blood pressure, waist and blood sugar?

During the 36 weeks on Zepbound, the trial participants' waist, blood pressure, blood fats and blood sugar measures improved along with their weight. The 2026 analysis followed those measures for the year after the switch to placebo and reported them separately for the four regain groups.3

After stopping, by regainHorn 2026
Measure

Mean change from the day of the switch to placebo to a year later, in 308 people. Blood pressure is the upper, systolic number. HbA1c is a three-month average of blood sugar, given in percentage points. Non-HDL cholesterol is given as a percent change.

Change over the year off the drugRegained under ¼¼ to ½½ to ¾¾ or more
Waist+0.8 cm+5.4 cm+10.1 cm+14.7 cm
Systolic blood pressure+6.8 mm Hg+7.3 mm Hg+9.6 mm Hg+10.4 mm Hg
HbA1c+0.14+0.15+0.27+0.35
Non-HDL cholesterol−0.4%+1.6%+8.4%+10.8%
Fasting insulin−4.0%+15.4%+46.2%+26.3%

Horn and colleagues, JAMA Internal Medicine 2026, post hoc analysis of SURMOUNT-4.

Waist follows the weight closely: almost no change in the group that kept its loss, and nearly 15 cm (about 6 inches) in the group that regained the most. Blood sugar and cholesterol move the same way, step by step with the amount regained.

Blood pressure is the exception worth noticing. It rose in every group, including by 6.8 mm Hg in the people who regained less than a quarter of their loss. Keeping the weight off did not keep all of the blood pressure benefit once the drug was gone. The analysis cannot say why, and a post hoc analysis of this kind is not designed to.

The authors' summary is that regaining a quarter or more of the lost weight "was associated with a greater reversal" of the earlier improvements, compared with holding the loss.3 The BMJ meta-analysis reached a similar result across many drugs: blood sugar, blood pressure, cholesterol and triglycerides were all projected to be back at their starting values within 1.4 years of stopping.4

For someone who started Zepbound with raised blood pressure or prediabetes, this is the practical point. Measures that looked settled on the drug are worth checking again in the months after it, on a schedule agreed with the prescriber, and the scale alone will not show them.

Is it the same after Wegovy or Ozempic?

The pattern is the same. Two trials of semaglutide 2.4 mg, the dose sold as Wegovy, tested what happens after stopping.

The first followed 327 participants of the STEP 1 trial for a year after their 68 weeks of treatment ended. Those who had taken semaglutide had lost 17.3% of their weight. A year after the last dose they had regained 11.6 percentage points and stood 5.6% below their starting weight. The authors' own words: participants "regained two-thirds of their prior weight loss".5 In kilograms the group's average went from 105.6 at the start to 87.5 at the end of treatment and 99.0 a year later, or from 233 lb to 193 lb and back to 218 lb.

The second, STEP 4, stopped the drug much earlier. After 20 weeks on semaglutide, in which people lost 10.6%, 803 participants were assigned to continue or to switch to placebo. Over the next 48 weeks the group that continued lost a further 7.9% and the group that stopped gained 6.9%.6

TrialDrugTime on the drug weeksLoss by thenA year after stoppingShare of the loss regained
SURMOUNT-4tirzepatide 10 or 15 mg3620.9%9.9% below the start53%
STEP 1 extensionsemaglutide 2.4 mg6817.3%5.6% below the start67%
STEP 4semaglutide 2.4 mg2010.6%4.4% below the start, after 48 weeks58%

Shares in the last column, and the STEP 4 figure in the fifth, are our arithmetic from the published percentages.

Three trials, three lengths of treatment, and in each one more than half of the loss returned within a year. Stopping after 20 weeks, 36 weeks or 68 weeks made no visible difference to that. None of these trials shows that a longer course protects against regain.

The table should not be read as a contest between the drugs. The trials differ in ways that affect the result. In SURMOUNT-4 the diet and activity counselling continued during the year off the drug. In the STEP 1 extension it ended together with the injections.5 The people, the length of treatment and the amount lost were different too. No trial has compared regain after tirzepatide with regain after semaglutide directly.

Two more details from the STEP 1 extension are useful. Almost half of the semaglutide group, 48.2%, were still at least 5% below their starting weight a year after stopping, down from 86.4% at the end of treatment. And people who had lost more on the drug tended to regain more in kilograms, yet still ended the year further below their starting weight than people who had lost less.5

Ozempic is the same substance at lower doses, approved for type 2 diabetes. The withdrawal trials above used the 2.4 mg dose in people without diabetes, so their numbers belong to Wegovy.

Is a lower dose a middle path?

One trial has tested it. In SURMOUNT-MAINTAIN, 441 adults took tirzepatide at 10 or 15 mg for 60 weeks. Then 378 of them were assigned to one of three paths for another year: stay on the same dose, step down to 5 mg, or switch to placebo.7

Loss from the starting weight at week 112
Stayed on 10 or 15 mg21.9%
Stepped down to 5 mg16.6%
Switched to placebo9.9%

The 5 mg dose held most of the loss. Compared with staying on the full dose, the step-down group ended about 5 points higher, and the placebo group 12 points higher. The authors call the 5 mg step-down "a valuable alternative to discontinuation".7

In pounds, for the 237 lb starting weight used in the calculator above, those three results are about 185 lb on the full dose, 198 lb on 5 mg and 214 lb after stopping. The step-down kept the person 16 lb below where stopping left them, and cost 13 lb against staying on the full dose. The two trials enrolled different people, so this is an illustration of the percentages and not a measured result.

The label allows it. Its recommended maintenance doses are 5, 10 or 15 mg, so a move from 15 mg to 5 mg stays inside the approved range.1 For someone whose reason for stopping is cost or side effects at the higher dose, this is the one alternative to stopping that has a randomized trial behind it. The dosing schedule covers the steps in both directions.

Should I taper off or stop at once?

The label does not ask for a taper. Its dosing section describes how to start, how to raise the dose and what to do about a missed dose. It has no schedule for coming off the drug, and it lists no withdrawal reaction from stopping.1

The trials stopped it at once. In SURMOUNT-4 and in the semaglutide trials, people went from their full dose to placebo from one week to the next. So the regain figures on this page are the figures for an abrupt stop.

In one sense the drug tapers itself. Because of the 5-day half-life, the level in the body drifts down over about five weeks, as the table above shows. Nobody goes from full effect to none overnight.

Whether stepping the dose down over several months before stopping leaves people with less regain a year later has not been tested in a randomized trial among the sources used here. The nearest evidence is SURMOUNT-MAINTAIN, and it tested staying on a lower dose, which is a different question from passing through one on the way out. A taper is something to plan with the prescriber. It is reasonable to ask for one, and equally reasonable to be told the evidence for it is thin.

Does exercise help hold the weight after stopping?

One randomized trial has looked at this, with an older drug of the same family. Researchers in Copenhagen first had adults with obesity lose 13.1 kg on an eight-week low-calorie diet. They then assigned them for one year to supervised exercise, to liraglutide 3.0 mg, to both, or to placebo. After the year, all treatment stopped, and the participants were weighed again a year later.8

The exercise was a real programme. Participants were asked to attend supervised group sessions twice a week, made of vigorous indoor cycling followed by circuit training, and to exercise twice a week more by themselves at moderate to vigorous intensity.

One year after all treatment stopped
Exercise plus drug, against drug alone5.1 kg lighter
Regain after drug alone, against exercise alone6.0 kg more
Odds of keeping a 10% loss, both against drug alone4.2 times

People who had exercised while on the drug held more of their loss a year after stopping than people who had only taken the drug. They were 5.1 kg lighter and had a body-fat percentage 2.3 points lower. In the year after treatment, weight regain was 6.0 kg greater after liraglutide alone than after exercise alone.8

The study also recorded what people did once the supervision ended. A year later, those who had been in the exercise groups reported a median of 225 to 240 minutes of moderate to vigorous activity a week. Those who had taken liraglutide without exercise reported 30 minutes. The habit built during treatment was still there.

The limits are plain. The drug was liraglutide, a daily injection that produces smaller losses than tirzepatide. Only 109 people came to the final weighing, and the range around the 5.1 kg estimate runs from 0.2 to 10.0 kg. It is still the best evidence available on the question, and it points one way: exercise started during treatment, and kept up afterwards, is the only non-drug measure in these sources with a measured effect on regain.

Why does the weight come back?

The shortest answer is in the label's description of how the drug works. Zepbound lowers weight by lowering calorie intake, and it does that "by affecting appetite".1 The effect lasts as long as the drug is in the body. Once the level has fallen away, over about five weeks, that effect is gone.

The trial design rules out a simpler explanation. If regain were mainly a matter of people dropping their diet and exercise plan, then continued counselling should have prevented much of it. In SURMOUNT-4 the counselling continued for the whole year, and the placebo group still regained half of the loss.1

The researchers who ran the semaglutide extension drew the general conclusion in their paper: the findings "confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health".5 In plain terms, they treat obesity as a long-term condition that the drug controls while it is taken, in the way that many long-term medicines work.

This also changes how a regain should be read. Across 37 studies and more than 9,000 people the same thing happened after the drug was stopped.4 A result that regular is a property of the treatment ending. It is not evidence of one person's weak will.

How many people stop, and why?

Most people who start one of these drugs for weight stop within a year. A study of US health records followed 125,474 adults with overweight or obesity who began liraglutide, semaglutide or tirzepatide between 2018 and 2023.9

Stopped within one year of starting
People without type 2 diabetes64.8%
People with type 2 diabetes46.5%

The study also looked at what went with stopping. People who were losing more weight were less likely to stop: among those without diabetes, each 1% of weight lost went with a 3.3% lower rate of discontinuation. People who had moderate or severe stomach and bowel side effects were more likely to stop, by 19% in the group without diabetes. Among people with diabetes, a higher income went with a lower rate of stopping.9

In the trials the numbers are lower, and still not small: 14.4% of those who started SURMOUNT-4 had left treatment by week 36, and during the second year 10.4% of the group still receiving Zepbound stopped their injections early.1

So stopping is the common case, not the unusual one. Anyone starting the drug is more likely than not to face the questions on this page within a year or two.

What if I stop and restart later?

Many people do. In the same health-record study, of the people who had stopped and had a weight on record, 36.3% of those without diabetes and 47.3% of those with it had restarted within a year. Regain was the trigger the data could see: each 1% of weight regained after stopping went with a 2.8% higher rate of restarting among people without diabetes.9

The label is short on how to restart. Its rule for a missed dose covers a delay of up to 4 days: take it within 96 hours, or skip it and take the next one on the usual day.1 It does not say what dose to use after a break of several weeks or months.

Two facts bear on that decision. The first is the level in the body: five weeks after the last injection, under a hundredth of the usual peak remains, so the body meets the drug again almost as if for the first time. The second is where side effects cluster. The label says most nausea, vomiting and diarrhea occurred during dose escalation, the period when the body is adjusting.1

The Wegovy label is more explicit about its own drug. After 2 or more missed doses in a row, it tells prescribers to "reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions".10 For Zepbound the restart dose is the prescriber's call, and it is worth asking about before stopping, not after. The article on missed doses shows how much drug is left after a gap of any length.

Does the drug work as well the second time?

None of the trials cited here stopped the drug and then restarted it in the same people, so they do not answer this. The health-record study counted who restarted. It did not report how much weight they lost on the second course.

What about stopping for pregnancy plans or surgery?

Pregnancy is the one situation in which the label itself tells people to stop: it says to discontinue Zepbound when a pregnancy is recognized.1 The UK medicines regulator goes a step earlier and advises stopping tirzepatide at least 1 month before trying to conceive.11 That lead time matches the level table above: after four to five weeks, almost none of the drug is left. The article on Zepbound and birth control covers contraception during treatment and the label's pregnancy section.

Surgery is different, and here the same UK guidance warns against stopping by one's own decision. Because these drugs slow the emptying of the stomach, it asks patients to tell the surgical team and the anaesthetist that they take one, so that the fasting instructions and the anaesthetic can be adjusted. It also tells patients to keep taking their prescribed medicines as usual unless the team says otherwise.11

What should be settled before the last dose?

The evidence above turns into a short list of things to agree with the prescriber while still on the drug.

  1. The reason, and the alternative that fits it. If the reason is cost or side effects at a high dose, the 5 mg step-down held a 16.6% loss in the trial where stopping left 9.9%. If the reason is a planned pregnancy, the UK lead time is one month.
  2. The starting line. Weight, waist and blood pressure on the day of the last dose. Everything later is compared with these.
  3. A date for checks. Blood pressure rose in every group after stopping, including the group that kept the weight off. A check in the following months finds that early.
  4. A weight at which to talk again. About a third of people restart within a year. Deciding the threshold in advance replaces a slow drift with a plan.
  5. The restart dose. The label does not give one after a long break, so ask what it would be.
  6. Exercise already under way. In the Copenhagen trial the benefit came from a programme that ran during treatment and continued afterwards. Starting on the day the drug stops is later than the trial tested.

What can these trials not tell you?

The numbers on this page are the best available, and they have edges.

They are averages. The same trial that produced "half comes back" contained people who regained under a quarter and people who regained nearly everything. The calculator shows the spread for that reason.

The course was short and uniform. Everyone in SURMOUNT-4 took the drug for exactly 36 weeks at 10 or 15 mg. Someone who has taken 5 mg for three years is not described by it. The semaglutide trials stopped at 20 and 68 weeks, with the same result, which suggests the length of the course is not what decides regain, but none of them tested several years.

Nobody had diabetes. People with type 2 diabetes were excluded from all three withdrawal trials. For them, stopping also removes a blood sugar treatment, and that is a separate conversation with the prescriber.

The follow-up was one year. What happens in the second and third year off the drug has been projected, not observed.

Some weights were missing. At week 88, body weight was missing for 13.7% of the placebo group and 7.5% of the Zepbound group, and the analysis filled those gaps with statistical methods described in the label.1

The makers ran the trials. SURMOUNT-4 and SURMOUNT-MAINTAIN were run by Eli Lilly, which sells Zepbound, and the STEP trials by Novo Nordisk, which sells Wegovy. The 2026 analysis of the regain groups was also sponsored by Eli Lilly. The BMJ meta-analysis was funded by a UK public research body, and the Copenhagen exercise trial by two Danish foundations, one of them the Novo Nordisk Foundation. A finding that people regain after stopping suits a company that sells a long-term treatment, so the independent meta-analysis is a useful check: it found the same regain across 37 studies.

Short answers to common questions

Will I regain all the weight if I stop Zepbound?

On average, no, not within a year. In the trial, people were still 9.9% below their starting weight a year after stopping, having regained about half of their loss. A projection in the BMJ meta-analysis puts the return to starting weight at about 1.5 years for semaglutide and tirzepatide, but no trial has followed people that long, and one in six kept most of their loss.

Is there a withdrawal reaction?

The label lists none and asks for no taper. The drug level falls gradually over about five weeks because of the 5-day half-life. What the trials recorded afterwards is weight regain.

How soon after the last dose does the effect wear off?

The first week is a normal week. By day 14 the level is at 17% of the usual peak, by day 21 at 6% and by day 35 under 1%.

Can I stop once I reach my goal weight?

You can, and the label does not forbid it, but it describes the drug as a treatment to "maintain weight reduction long term". In the trial, reaching a 20.9% loss and then stopping was followed by a regain of half of it within a year. A lower maintenance dose is the tested alternative.

I stopped three weeks ago. Can I take my old dose again?

The label's missed-dose rule ends at 4 days and does not cover this. At three weeks the level is about 6% of the usual peak. Ask the prescriber before injecting: the Wegovy label, for its own drug, restarts the escalation at a lower dose after two missed doses.

Does it matter how long I was on it?

Not in the trials so far. Stopping after 20, 36 or 68 weeks was followed by a regain of more than half of the loss within a year in each case.

Is regain slower after Zepbound than after Wegovy?

That has not been compared directly. The trials differ in length, in the people enrolled and in whether lifestyle counselling continued, so their percentages cannot be set against each other as a ranking.

Will my blood pressure go back up?

In the trial it rose after stopping in every group, by 6.8 mm Hg in people who kept most of their weight loss and by 10.4 mm Hg in those who regained the most. It is worth measuring in the months after the last dose.

Can I inject every two weeks instead of stopping?

The label describes weekly dosing only, and none of the trials here tested longer gaps between injections. The option with trial evidence is a lower weekly dose: 5 mg held a 16.6% loss over a year.

How the calculator works

The calculator takes the weight you have lost and applies the two average outcomes of SURMOUNT-4. For stopping, it returns 53% of the lost weight: the trial's participants lost 20.9% and were 9.9% below their starting weight a year after stopping, so 11 of 20.9 points came back. For staying on, it takes 5.5% off your current weight, the change measured from week 36 to week 88. Both lines are drawn straight between today and week 52, because the published results give the two ends and not the weeks in between.

The shaded wedge uses the four regain groups from the 2026 analysis of the same trial: under a quarter of the loss regained (18 in 100 people), a quarter to a half (25), half to three quarters (33), and three quarters or more (24). The dots chart rounds the trial's 16.6% and 89.5% to whole people. The bars for waist, blood pressure, HbA1c and cholesterol show the published mean changes in each group. The level table comes from our one-compartment model with the label's half-life of 5 days.

The trial tested stopping after 36 weeks on 10 or 15 mg in people without diabetes. If your course was shorter, longer or on a lower dose, the calculator still does the same arithmetic, and the result is further from anything the trial measured.

Sources

  1. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2.1 to 2.3, 6.1, 8.1, 12.1 to 12.3 and 14.1 (Study 4). accessdata.fda.gov
  2. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
  3. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Intern Med 2026;186:157-167. doi:10.1001/jamainternmed.2025.6112
  4. West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 2026;392:e085304. doi:10.1136/bmj-2025-085304
  5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564. doi:10.1111/dom.14725
  6. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
  7. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
  8. Jensen SBK, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 2024;69:102475. doi:10.1016/j.eclinm.2024.102475
  9. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open 2025;8:e2457349. doi:10.1001/jamanetworkopen.2024.57349
  10. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 2.4. accessdata.fda.gov
  11. Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. Guidance, updated 5 February 2026. gov.uk

Related analyses

Log your weight and see your own line next to the trial's.

Open Dose Insider